[Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].
Turisteron proves to be a highly effective, poor in side effects, orally applicable estrogen preparation for the hormone therapy of the carcinoma of the prostate under the conditions of the routine practice. The cumulative 5-year survival rates of 197 patients observed of all categories of tumours (T1-4NxM0-1) were 66 +/- 10% and were depending upon the local growth of the tumour and upon the degree of metastasation between 81 +/- 18% and 47 +/- 42%. A discontinuation of the therapy due to strong side effects was necessary only in 4 cases (2.07%).
Guddat
H M
HM
Schnorr
D
D
Zemke
F
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
C025723:ethinyl estradiol sulfonate; D004997:Ethinyl Estradiol
Erste Ergebnisse der multizentrischen klinischen Prüfung Stufe IV von Turisteron zur Therapie des Prostatakarzinoms.